TL;DR
Get your next haul delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Sobi’s Nomination Committee has proposed Börje Ekholm for election as a board member and chair at the company’s 2027 Annual General Meeting. Current chair David Meek will remain in the role until May 2027 and has said he will not stand for re-election. Shareholders have not yet voted on Ekholm’s proposed appointment.
Sobi’s Nomination Committee has proposed that Börje Ekholm be elected as a board member and chair at the company’s 2027 Annual General Meeting, setting out a planned leadership change at the Swedish biopharmaceutical company. Current chair David Meek will serve through the end of his term in May 2027 and has decided not to seek re-election.
The proposal is not an appointment: shareholders must elect Ekholm at the AGM. Sobi said the committee will publish its full proposals before the meeting, but did not give a date for that publication. The announcement was released on October 29, 2026, under the EU Market Abuse Regulation.
Ekholm brings more than 30 years of experience in technology, investment management and international business leadership, according to Sobi. He recently stepped down as chief executive of Ericsson and previously led Patricia Industries and Investor AB. He currently chairs Trimble and is due to join Nasdaq Inc.’s board on November 1, 2026.
Sobi also pointed to Ekholm’s prior connection to the company. During his time as Investor AB chief executive, he was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International, and worked with the company from an ownership perspective. His past board roles include Alibaba, Husqvarna, Nasdaq, Scania and WM Data, according to the announcement.
A Leadership Change at Sobi
The proposal would bring a chair with prior familiarity with Sobi and experience across international companies to the board’s leadership. The chair helps guide board oversight and governance; the role is distinct from running the company’s daily operations. The announcement does not describe a change to Sobi’s executive leadership or operating strategy.
The timing gives the company and shareholders several months before Meek’s term ends. Sobi said that during Meek’s tenure the company delivered strong growth and shareholder returns, expanded access to its medicines through new launches and indication extensions, and strengthened its clinical development pipeline. Those are Sobi’s account of its performance; the release does not provide figures or detail against which to assess those statements.
For investors, the immediate development is a nomination rather than a completed handover. The formal decision rests with shareholders at the 2027 AGM. Ekholm’s prior involvement in Sobi’s formation may be relevant to his familiarity with the company, but the release does not specify what priorities he would pursue if elected.
Products Worth Considering
Bose TV Speaker Compact Soundbar with Bluetooth and HDMI-ARC, Black
Bose Lifestyle Ultra Wireless Home Speaker
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Meek’s Term and Ekholm’s Sobi Ties
Meek has served on Sobi’s board and as its chair since December 2024. The company says he will continue in the chair role until May 2027, the end of his current term. His decision not to stand for another term is the reason the committee is proposing a successor.
Sobi, formally Swedish Orphan Biovitrum AB, is a biopharmaceutical company focused on rare diseases. The company says it has about 2,000 employees across Europe, North America, the Middle East, Asia and Australia. It reported revenue of SEK 28 billion in 2025, and its shares are listed on Nasdaq Stockholm. Ekholm’s historical connection dates to his leadership at Investor AB, when he was involved in the merger that created Sobi.
Ekholm’s election is not yet confirmed. The announcement does not give the date of the 2027 AGM or state whether any other candidates will be proposed. Sobi said the committee’s full proposals will be published in due time before the meeting.
The release also does not set out Ekholm’s views on the chair role, his intended priorities, or any planned changes to board composition beyond this proposed succession. Details on those points remain unavailable in the announcement.
Steps Toward the 2027 AGM
Sobi’s Nomination Committee is expected to publish its complete proposals ahead of the 2027 AGM. Shareholders will then consider whether to elect Ekholm as both a board member and chair. Until that vote and the end of Meek’s current term in May 2027, Meek is due to remain chair, according to Sobi.
Key Questions
Has Börje Ekholm been appointed chair of Sobi?
No. Sobi’s Nomination Committee has proposed him for election as a board member and chair. Shareholders must vote on the proposal at the 2027 AGM.
When will David Meek leave the chair role?
Sobi says Meek will continue as chair until the end of his current term in May 2027. He has decided not to stand for re-election at the 2027 AGM.
Why was Ekholm proposed?
The committee cited his global leadership and board experience and familiarity with Sobi. During his time as Investor AB chief executive, he was involved in the merger that created the company.
When will shareholders vote?
The vote is expected at Sobi’s 2027 Annual General Meeting. The announcement does not provide the meeting date; the committee said its full proposals will be published before the AGM.
Source: prnewswire.com
